A Study Evaluating the Efficacy and Safety of Lebrikizumab in Adult Patients With Mild to Moderate Asthma

Phase 3

Completed

• Conditions: Asthma
• Interventions: Drug: lebrikizumab; Drug: montelukast [Singulair]; Other: placebo

• Registration Number: NCT02104674
• Lead Sponsor: Hoffmann-La Roche

Brief Summary

This Phase III, randomized, double-blind, placebo-controlled, multicenter study will assess the efficacy and safety of lebrikizumab in adult patients with mild to moderate asthma treated with short-acting beta-agonist (SABA) therapy alone. Patients will be randomized in a 1:1:1 ratio to receive either blinded lebrikizumab or placebo treatment by subcutaneous (SC) injection (every 4 weeks for a total of 3 doses) or open-label treatment with Singulair (Montelukast; 10 mg daily). Time on study treatment will last 12 weeks.

Detailed Description

Not available

Study Timeline

• Study First Submitted: 2014-03-26
• Study First Submitted QC: 2014-04-02
• Study First Posted: 2014-04-04
• Study Start: 2014-06
• Primary Completion: 2016-05
• Study Completion: 2016-05
• Status Verified: 2016-11
• Last Update Submitted: 2016-11-01
• Last Update Posted: 2016-11-02

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 313

Inclusion Criteria

• Age 18-75 years old at study start
• Asthma diagnosis for >/= 12 months prior to study start
• Bronchodilator response at screening
• Pre-bronchodilator FEV1 of 60% - 85% predicted at both screening visits 2 and 3
• No other clinically significant lung disease as confirmed by chest X-ray or computed tomography (CT) scan
• Stable and symptomatic asthma during the screening period
• Use of effective contraception, as defined by the protocol, until 24 weeks after the last dose

Read More

Exclusion Criteria

• Maintenance of corticosteroid therapy, defined as daily or alternate-day oral corticosteroid maintenance therapy within 3 months prior to study start
• Treatment with systemic or inhaled corticosteroids within 4 weeks prior to study start or during the screening period for any reason, including an acute exacerbation event
• Treatment with a leukotriene receptor antagonist (LTRA), long-acting beta-agonist (LABA) long-acting muscarinic antagonist (LAMA), zileuton, roflumilast, or theophylline within 2 weeks prior to study start
• Documented prior treatment failure with Montelukast
• Treatment with intra-articular corticosteroids within 4 weeks prior to study start or during the screening period or anticipated need for intra articular corticosteroids during the course of the study
• Any infection requiring hospital, IV or IM antibiotic treatment or any respiratory infection within 4 weeks of study start. Any infection requiring oral antibiotic treatment within 2 weeks of study start, or any parasitic infection within 6 months of study start
• Clinically significant abnormality found during screening or clinically significant medical disease that is uncontrolled despite treatment that is likely, in the opinion of the investigator, to impact the patient's ability to participate in the study, or impact the study assessments
• History of interstitial lung disease, chronic obstructive pulmonary disease (COPD), or other clinically significant lung disease other than asthma
• History of alcohol or drug abuse that would impair or risk the patient's full participation in the study, in the opinion of the investigator
• Current or history of smoking (> 10 pack-years), or unwillingness to abstain from smoking for the duration of the study
• Past and/or current use of any anti-IL-13 or anti- IL4/IL-13 therapy, including lebrikizumab
• Use of a licensed or investigational monoclonal antibody other than anti IL-13 or anti-IL-4/IL-13, including, but not limited to, omalizumab, anti-IL-5, or anti IL-17, within 6 months or 5 drug half-lives prior to Visit 1 (whichever is longer) or during screening
• Use of a systemic immunomodulatory or immunosuppressive therapy within 3 months or 5 drug half-lives prior to study start or during screening
• Use of other investigational therapy within 4 weeks or 5 drug half-lives prior to study start (whichever is longer) or during screening
• Initiation of or change in allergen immunotherapy within 3 months prior to study start or during screening
• Receipt of a live attenuated vaccine within 4 weeks prior to study start of during screening
• Pregnancy or breast feeding
• Body mass index > 38 kg/m2
• Body weight < 40 kg
• History of bronchial thermoplasty

Read More

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: PARALLEL

Arm && Interventions

Group	Intervention	Description
lebrikizumab	lebrikizumab	-
Singulair (montelukast)	montelukast [Singulair]	-
Placebo	placebo	-

Primary Outcome Measures

Name	Time	Method
Absolute change in pre-bronchodilator forced expiratory volume in 1 second (FEV1)	From Baseline to Week 12

Secondary Outcome Measures

Name	Time	Method
Relative change in morning pre-bronchodilator peak expiratory flow (PEF)	From Baseline to Week 12
Time to treatment failure	From Baseline to Week 12
Pharmacokinetics: Maximum serum lebrikizumab concentration after the first dose (Cmax)	Week 1
Change in patient-reported outcome, as measured by the Standardized Asthma Quality of Life Questionnaire (AQLQ(S))	From Baseline to Week 12
Change in asthma rescue medication use	From Baseline to Week 12
Incidence of adverse events	Approximately 20 weeks
Pharmacodynamics: Change in blood eosinophil count	From Baseline to Week 12
Pharmacodynamics: Relative change in fractional exhaled nitric oxide (FeNO)	From Baseline to Week 12